The rising prevalence of chronic conditions such as hypogonadism in adult men worldwide is expected to drive growth in the hormone replacement therapy market. According to the European Association of Urology, male hypogonadism is a disorder associated with decreased functional activity of the testes, decreased production and/or action of androgens, and/or impaired sperm production in June 2021. Hormone Replacement Therapy Market is due to poor testicular function or insufficient stimulation of the testes by the hypothalamic-pituitary-gonadal (HPG) axis. Similarly, several congenital or acquired disorders causing androgen dysfunction have been described. The prevalence of symptomatic hypogonadism in men aged 40 to 79 years ranges from 2.1% to 5.7%.
Read More @ https://cmiinfonest.blogspot.com/2023/02/the-global-hormone-replacement-therapy.html
